IP Library Granted Patent US 9,896,486
Granted Patent B2
US 9,896,486 · App. 14/903,837 · Granted Feb 20, 2018

Mutated immunoglobulin-binding polypeptides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,896,486
App. No.
14/903,837
Granted
Feb 20, 2018
Kind
B2
Abstract

A polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A, as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamine residue at position 9 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.

Claims (18)

1. A polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamine residue at position 9 has been mutated to an amino acid other than asparagine, comprising a sequence selected from the group consisting of: SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 20, SEQ ID NO 25, SEQ ID NO 26 and SEQ ID NO 27.

2. The polypeptide or multimer according claim 1 , further comprising at the C-terminal or N-terminal one or more coupling element, selected from the group consisting of a cysteine residue, a plurality of lysine residues and a plurality of histidine residues.

3. A nucleic acid or a vector encoding a polypeptide or multimer according to claim 1 .

4. A separation matrix, wherein a plurality of polypeptides or multimers according to claim 1 have been coupled to a solid support.

5. A method of isolating an immunoglobulin, wherein a separation matrix according to claim 4 is used.

6. The method of claim 5 , comprising the steps of:

contacting a liquid sample comprising an immunoglobulin with the separation matrix,

washing said separation matrix with a washing liquid,

eluting the immunoglobulin from the separation matrix with an elution liquid, and cleaning the separation matrix with a cleaning liquid.

7. The polypeptide of claim 1 , wherein the sequence is SEQ ID NO 6.

8. The polypeptide of claim 1 , wherein the sequence is SEQ ID NO 7.

9. The polypeptide of claim 1 , wherein the sequence is SEQ ID NO 8.

10. The polypeptide of claim 1 , wherein the sequence is SEQ ID NO 9.

11. The polypeptide of claim 1 , wherein the sequence is SEQ ID NO 10.

12. The polypeptide of claim 1 , wherein the sequence is SEQ ID NO 20.

13. The polypeptide of claim 1 , wherein the sequence is SEQ ID NO 25.

14. The polypeptide of claim 1 , wherein the sequence is SEQ ID NO 26.

15. The polypeptide of claim 1 , wherein the sequence is SEQ ID NO 27.

Assignments (3)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054299/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2017
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 043619/0648 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2016
From: RODRIGO, GUSTAV; ANDER, MATS; BJORKMAN, TOMAS; BAUREN, GORAN
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 037440/0823 →